The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Letter to the editor
Editor, – The following drugs have all been (relatively) recently marketed (except Zentel/albendazole, but it is coming soon), have names beginning with 'Z' and are of two syllables. Surely, this is sowing the seeds of confuzion, with perhaps dire conzequences?
|
Zadine |
Zantac |
Zentel |
|
Zestril |
Zocor |
Zofran |
|
Zoloft |
Zoton |
Zyrtec |
Cheerz
Dr Alain Rohan
Zecretary
and Dr Ian Boyd
Adverse Drug Reactions Advisory Committee
Editorial note
No commentz.
| Guidelines for the rational use of benzodiazepines |
| The Royal Australian College of General Practitioners has recently reviewed its 'Guidelines for the rational use of benzodiazepines'. These are available from The Royal Australian College of General Practitioners PO Box 906 Rozelle NSW 2039. |
| Australian Statistics on medicines |
| The second edition of Australian Statistics on Medicines, which presents dispensing data on the community (non-hospital) use of most drugs marketed in Australia from 1990 to 1992, is now available from the Australian Government Publishing Service (Free call 008 020 049) at a cost of $34.95. |